FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.96 USD
0 (0%)
Historical Prices
From:
To:
About
ceo
Mr. William D. Baird III, M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.2seventybio.comexchange
NASDAQ
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
CIK
0001860782
ISIN
US9013841070
CUSIP
901384107
Address
60 Binney Street
Phone
339 499 9300
Country
US
Employee
65
IPO Date
Nov 3, 2021
Financial Statement
Earnings
TSVT Financial Summary
CIK
0001860782
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
901384107
ISIN
US9013841070
Country
US
Price
4.96
Beta
1.05
Volume Avg.
1.21M
Market Cap
259.6M
Shares
-
52-Week
2.29-5.3
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-4.51
P/B
-
Website
https://www.2seventybio.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TSVT News
Danny Green
Mar 19, 2025
2seventy bio, Inc. (NASDAQ:TSVT) Sees Positive Analyst Senti...
2seventy bio, Inc. (NASDAQ:TSVT) is a biotechnology company based in Cambridge, Massachusetts, specializing in cell and gene therapies for cancer treatment. The company is known for its CAR-T cell product candidates and has a significant collaboration with Bristol-Myers Squibb Company. This partnership is crucial for advancing their pipeline and enhancing their market presence. The consensus price target for TSVT has seen a notable increase over the past year, rising from $3.5 to $5. This upwar...
Stuart Mooney
Mar 17, 2025
2seventy bio, Inc. (NASDAQ:TSVT) Earnings Outlook and Financ...
2seventy bio, Inc. (NASDAQ:TSVT) is preparing to announce its quarterly earnings on March 18, 2025. Analysts expect the company to report an earnings per share (EPS) of -$0.20 and revenue of about $13 million. Despite these projections, the company has recently been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings potential. The Zacks Rank upgrade suggests that TSVT's stock might see upward movement soon. This ranking system is based on a company's evolving earni...
Tony Dante
Nov 12, 2024
2Seventy Bio Inc. (NASDAQ:TSVT) Faces Challenges Amid Compet...
2Seventy Bio Inc. (NASDAQ:TSVT) is a biotechnology company focused on developing innovative therapies for cancer treatment. The company operates in a competitive landscape, with peers like Bluebird Bio and CRISPR Therapeutics. On November 12, 2024, Goldman Sachs reiterated its "Sell" rating for TSVT, maintaining a "hold" action, with the stock priced at approximately $4.31, as highlighted by StreetInsider. During its Q3 2024 earnings call, 2Seventy Bio reported a quarterly loss of $0.18 per sha...
Seeking Alpha
Aug 11, 2024
2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript
2seventy bio, Inc. (NASDAQ:TSVT ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs William Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer Anna Truppel-Hartmannn - Chief Medical Officer Conference Call Participants Daina Graybosch - Leerink Kelsey Goodwin - Guggenheim Securities Operator Good day, and thank you for standing by. Welcome to the 2Seventy Bio Second Quarter 2024 Earnings Con...
Zacks Investment Research
Aug 7, 2024
2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Esti...
2seventy bio, Inc. (TSVT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.83 per share a year ago.
Zacks Investment Research
Aug 5, 2024
Is the Options Market Predicting a Spike in 2seventy bio (TS...
Investors need to pay close attention to 2seventy bio (TSVT) stock based on the movements in the options market lately.
Zacks Investment Research
Aug 5, 2024
Will 2seventy bio, Inc. (TSVT) Report Negative Q2 Earnings? ...
2seventy bio, Inc. (TSVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seeking Alpha
Jul 9, 2024
2seventy bio's Abecma: Compelling Investment In Multiple Mye...
2seventy bio, Inc. focuses on Abecma, an FDA-approved CAR T cell therapy for multiple myeloma. TSVT's strategic realignment includes selling non-core assets to Regeneron and Novo Nordisk. Abecma shows favorable clinical data but faces strong competition from Carvykti.
